The U.S. Food and Drug Administration (FDA) announced a virtual meeting will take place on February 15, 2022, to discuss the request for emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine for use in children 6 months through 4 years of age.
Previously, the FDA authorized this mRNA vaccine for use in children 5 through 11 years of age in October 2021 and recently authorized the use of a single booster dose in individuals 12 through 15 years of age and older.
U.S. FDA Discussing COVID-19 Vaccinations for Infants
Intention to Receive COVID-19 Vaccine Has Grown Faster Among Black Adults
Persistent lower vaccination rate in Black adults might be explained by other factors besides hesitancy
Physician Mental Health Has Declined During the Pandemic
Findings show an increase in mental health, substance use-related visits among Canadian physicians
Risk for Breakthrough SARS-CoV-2 Infection Lower With mRNA-1273
Risk for breakthrough infection and of 60-day hospitalization significantly lower for mRNA-1273 versus BNT162b2 vaccination
Pfizer Asks FDA to Approve Its Vaccine for the Youngest Children
An FDA advisory panel will weigh the two-dose regimen on Feb. 15
Unvaccinated Have Highest SARS-CoV-2 Incidence, Hospitalization
Unvaccinated persons have higher rates of incidence, hospitalization during periods of delta, omicron predominance